Drug safety evaluation of intravitreal triamcinolone acetonide

Bibliography

• Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-80
   PubMedGoogle Scholar
• Scholes GN, O'Brien WJ, Abrams GW, Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-9
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6
   PubMed Web of Science ®Google Scholar
• Inoue M, Takeda K, Morita K, Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 2004;138:1046-8
   PubMed Web of Science ®Google Scholar
• Bandello F, Pognuz DR, Pirracchio A, Intravitreal triamcinolone acetonide for florid proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2004;242:1024-7
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Weaver CD, Gallagher MJ, Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009;116:902-11
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-45
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25
   PubMed Web of Science ®Google Scholar
• Singh CN, Saperstein DA. Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration. Retina 2008;28:789-93
   PubMed Web of Science ®Google Scholar
• Rechtman E, Allen VD, Danis RP, Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003;136:739-41
   PubMed Web of Science ®Google Scholar
• Ip MS, Scott IU, Van Veldhuisen PC, A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14
   PubMed Web of Science ®Google Scholar
• Scott IU, Ip MS, Van Veldhuisen PC, A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmol Scand 2003;81:540-1
   PubMedGoogle Scholar
• Chen W, Chen H, Hou P, Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy. Retina 2011;31:1137-42
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384-6
   PubMed Web of Science ®Google Scholar
• Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-16
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol 2004;137:367-8
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. Eur J Ophthalmol 2003;13:575-6
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intravitreal triamcinolone acetonide as treatment for extensive exudative retinal detachment. Br J Ophthalmol 2004;88:587-8
   PubMed Web of Science ®Google Scholar
• Sutter FK, Gillies MC. Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 2003;121:1491-3
   PubMed Web of Science ®Google Scholar
• Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 2005;83:248-51
   PubMedGoogle Scholar
• Karacorlu M, Arf Karacorlu S, Ozdemir H. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome. Eur J Ophthalmol 2006;16:481-3
   PubMed Web of Science ®Google Scholar
• Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol 2009;3:41-7
   PubMedGoogle Scholar
• Gopal L, Sharma T. Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration. Indian J Ophthalmol 2007;55:431-5
   PubMedGoogle Scholar
• Sobrin L, D'Amico DJ. Controversies in intravitreal triamcinolone acetonide use. Int Ophthalmol Clin 2005;45:133-41
   PubMedGoogle Scholar
• Spandau UH, Derse M, Schmitz-Valckenberg P, Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003
   PubMed Web of Science ®Google Scholar
• Audren F, Tod M, Massin P, Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:3435-41
   PubMed Web of Science ®Google Scholar
• Pharmacology review(s): FDA/Center for Drug Evaluation and Research, 2008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022220s000_PharmR.pdf [Last accessed 25 June 2011]
   Google Scholar
• Degenring RF, Jonas JB. Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:1142-3
   PubMed Web of Science ®Google Scholar
• Abelson MB, Butrus S. Corticosteroids in ophthalmic practice. In: Abelson MB, Neufeld AH, Topping TM, editors. Principles and practice of ophthalmology. Saunders; Philadelphia, PA: 1994. p. 1014
   Google Scholar
• Tsaprouni LG, Ito K, Punchard N, Adcock IM. Triamcinolone acetonide and dexamethasome suppress TNF-alpha-induced histone H4 acetylation on lysine residues 8 and 12 in mononuclear cells. Ann NY Acad Sci 2002;973:481-3
   PubMed Web of Science ®Google Scholar
• Tong JP, Lam DS, Chan WM, Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis 2006;12:1490-5
   PubMed Web of Science ®Google Scholar
• Zhang SX, Wang JJ, Gao G, Pigment epithelium-derived factor (PEDF) is an endogenous antinflammatory factor. FASEB J 2006;20:323-5
   PubMed Web of Science ®Google Scholar
• Juergens UR, Jager F, Darlath W, Comparison of in vitro-activity of commonly used topical glucocorticoids on cytokine- and phospholipase inhibition. Eur J Med Res 2004;31:383-90
   Google Scholar
• Mizuno S, Nishiwaki A, Morita H, Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest Ophthalmol Vis Sci 2007;48:2831-6
   PubMed Web of Science ®Google Scholar
• Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111:2044-9
   PubMed Web of Science ®Google Scholar
• Ciardella AP, Klancnik J, Schiff W, Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004;88:1131-6
   PubMed Web of Science ®Google Scholar
• Micelli Ferrari T, Sborgia L, Furino C, Intravitreal triamcinolone acetonide: evaluation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. Eur J Ophthalmol 2004;14:321-4
   PubMed Web of Science ®Google Scholar
• Lee WF, Yang CM. Intravitreal triamcinolone injection for macular edema secondary to increased retinal vascular permeability. J Formos Med Assoc 2004;103:692-700
   PubMed Web of Science ®Google Scholar
• Karacorlu M, Ozdemir H, Karacorlu S, Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 2005;19:382-6
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kamppeter B. Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. Cornea 2006;25:240-1
   PubMed Web of Science ®Google Scholar
• Jonas JB, Vossmerbaeumer U, Kamppeter BA. Chronic prephthisical ocular hypotony treated by intravitreal triamcinolone acetonide. Acta Ophthalmol Scand 2004;82:637
   PubMedGoogle Scholar
• Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12
   PubMed Web of Science ®Google Scholar
• Benz MS, Murray TG, Dubovy SR, Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-3
   PubMed Web of Science ®Google Scholar
• Jonas JB, Bleyl U. Morphallaxia-like ocular histology after intravitreal triamcinolone acetonide. Br J Ophthalmol 2004;88:839-40
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-4
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Spandau UH, Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-80
   PubMed Web of Science ®Google Scholar
• Kreissig I, Degenring RF, Jonas JB. Intravitreal triamcinolone acetonide Complication of infectious and sterile endophthalmitis. Ophthalmologe 2006;103:30-4
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU, Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6
   PubMed Web of Science ®Google Scholar
• Parke DW. Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 2003;136:918-19
   PubMed Web of Science ®Google Scholar
• Westfall AC, Osborn A, Kuhl D, Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005;123:1075-7
   PubMed Web of Science ®Google Scholar
• Nelson ML, Tennant MT, Sivalingam A, Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-91
   PubMed Web of Science ®Google Scholar
• Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-4
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Scott IU, Flynn HW, Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138:489-92
   PubMed Web of Science ®Google Scholar
• Roth DB, Chieh J, Spirn MJ, Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-82
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal J, Agrawal TP. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138:679-80
   PubMed Web of Science ®Google Scholar
• Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol 2006;124:133-4
   PubMed Web of Science ®Google Scholar
• Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-7
   PubMedGoogle Scholar
• Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-90
   PubMed Web of Science ®Google Scholar
• Bui Quoc E, Bodaghi B, Adam R, Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis. J Fr Ophtalmol 2002;25:1048-56
   PubMed Web of Science ®Google Scholar
• Chan CK, Fan DS, Chan WM, Ocular-hypertensive response and corneal endothelial changes after intravitreal triamcinolone injections in Chinese subjects: a 6-month follow-up study. Eye 2005;19:625-30
   PubMed Web of Science ®Google Scholar
• Detry-Morel M, Escarmelle A, Hermans I. Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. Bull Soc Belge Ophtalmol 2004;292:45-51
   PubMedGoogle Scholar
• Gillies MC, Kuzniarz M, Craig J, Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112:139-43
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Billson FA, Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-40
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kreissig I, Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-8
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring R, Kreissig I, Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-5
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003;121:729-30
   PubMed Web of Science ®Google Scholar
• Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-8
   PubMed Web of Science ®Google Scholar
• Singh IP, Ahmad SI, Yeh D, Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004;138:286-7
   PubMed Web of Science ®Google Scholar
• Smithen LM, Ober MD, Maranan L, Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-3
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring R, Vossmerbauemer U, Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol 2005;15:462-4
   PubMed Web of Science ®Google Scholar
• Gillies MC, Islam FM, Zhu M, Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007;91:1323-6
   PubMed Web of Science ®Google Scholar
• Cekic O, Chang S, Tseng JJ, Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005;139:993-8
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Szurman P, Bartz-Schmidt KU. Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmologe 2004;101:121-8
   PubMed Web of Science ®Google Scholar
• Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-48
   PubMed Web of Science ®Google Scholar
• Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol 2006;244:1152-9
   PubMed Web of Science ®Google Scholar
• Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007;245:817-24
   PubMed Web of Science ®Google Scholar
• Lang Y, Zemel E, Miller B, Retinal toxicity of intravitreal kenalog in albino rabbits. Retina 2007;27:778-88
   PubMed Web of Science ®Google Scholar
• Yeung CK, Chan KP, Chan CK, Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004;48:236-42
   PubMed Web of Science ®Google Scholar
• Tokuda K, Tsukamoto T, Fujisawa S, Evaluation of toxicity due to vital stains in isolated rat retinas. Acta Ophthalmol Scand 2004;82:189-94
   PubMedGoogle Scholar
• Kivilcim M, Peyman GA, El-Dessouky ES, Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000;31:474-8
   PubMedGoogle Scholar
• Narayanan R, Mungcal JK, Kenney MC, Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 2006;47:722-8
   PubMed Web of Science ®Google Scholar
• Yeung CK, Chan KP, Chiang SW, The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003;44:5293-300
   PubMed Web of Science ®Google Scholar
• Ozurdex Geneva Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46
   PubMed Web of Science ®Google Scholar
• Pearson PA, Comstock T, Ip M, Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-7
   PubMed Web of Science ®Google Scholar
• Ozdek S, Bahceci UA, Gurelik G, Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complications 2006;20:246-51
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005;139:290-4
   PubMed Web of Science ®Google Scholar
• Bonini-Filho MA, Jorge R, Barbosa JC, Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-9
   PubMed Web of Science ®Google Scholar
• Veritti D, Lanzetta P, Perissin L, Bandello F. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up. Invest Ophthalmol Vis Sci 2009;50:2391-7
   PubMed Web of Science ®Google Scholar
• Tao Y, Jonas JB. Intravitreal triamcinolone. Ophthalmologica 2011;225:1-20
   PubMed Web of Science ®Google Scholar
• Veritti D, Perissin L, Zorzet S, The effect of triamcinolone acetonide, sodium hyaluronate, and chondroitin sulfate on human endothelial cells: an in vitro study. Eur J Ophthalmol 2010;21:75-9
   Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Audren F, Erginay A, Haouchine B, Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006t;84:624-30
   PubMedGoogle Scholar
• Cardillo JA, Melo LA, Costa RA, Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-63
   PubMed Web of Science ®Google Scholar
• Dehghan MH, Ahmadieh H, Ramezani A, A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 2008;28:7-17
   PubMedGoogle Scholar
• Gillies MC, Simpson JM, Gaston C, Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116:2182-7
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kamppeter BA, Harder B, Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-7
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-9
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohamed S, A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91:199-203
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W, A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-73
   PubMed Web of Science ®Google Scholar
• Dada T, Dhawan M, Garg S, Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract. J Cataract Refract Surg 2007;33:1613-18
   PubMed Web of Science ®Google Scholar